C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Position in BioNTech SE (NASDAQ:BNTX)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,810 shares of the company’s stock, valued at approximately $1,118,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Baillie Gifford & Co. lifted its stake in shares of BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC increased its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC purchased a new position in BioNTech during the 3rd quarter valued at about $59,485,000. DekaBank Deutsche Girozentrale increased its holdings in BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock valued at $56,886,000 after acquiring an additional 53,800 shares in the last quarter. Finally, abrdn plc increased its holdings in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock valued at $43,947,000 after acquiring an additional 159,676 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 2.4 %

Shares of BNTX stock opened at $122.75 on Wednesday. The stock has a market cap of $29.43 billion, a price-to-earnings ratio of -58.45 and a beta of 0.17. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm’s 50 day moving average price is $117.32 and its two-hundred day moving average price is $110.18.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target for the company. Finally, TD Cowen lowered their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.